Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins
Description of Invention:
The invention provides for a full-length cloned cDNA copy of the RNA genome of a predominant norovirus strain (Genogroup II.4) designated MD145-12 that was associated with human gastrointestinal illness. The noroviruses, which were formerly known as "Norwalk-like" viruses are estimated to cause 23 million cases of acute gastroenteritis in the USA each year. The virus has been designated into category B of the CDC biodefense-related priority pathogens because it can be used as an agent of bioterrorism. The subject cDNA clone of the virus encodes proteins of the MD145-12 strain that, when expressed in vitro, exhibit properties that would be expected from those produced by the original infectious virus. This cDNA clone is presently the only source to obtain norovirus proteins to facilitate studies aimed at developing control strategies such as vaccines and therapeutic drugs.
Inventors:
Gael M. Belliot (NIAID) Kim Y. Green (NIAID) Stanislav V. Sosnovtsev (NIAID)
Patent Status:
DHHS Reference No. E-212-2003/0 -- Research Material
Related Technologies:
DHHS Reference No. E-198-2003/0 -- Research Material
Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, from Calicivirus Strains (including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)
DHHS Reference No. E-214-2003/0 -- Research Material
Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome
DHHS Reference No. E-283-2003/0 -- Research Material
Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus)
Licensing Status: The cDNA clone for norovirus strain MD145-12 is available for licensing via a biological material license (BML).
Collaborative Research Opportunity:
The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize reagents derived from a cDNA clone of the genome of a predominant human norovirus strain, Genogroup II.4. Please contact Kim Y. Green at kgreen@niaid.nih.gov for more information.
For Additional Information Please Contact: Peter A. Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4646
Email: soukasp@mail.nih.gov
Fax: (301) 402-0220
